Cargando…
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
Understanding individual differences in the susceptibility to metabolic side effects as a response to antipsychotic therapy is essential to optimize the treatment of schizophrenia. Here we perform genomewide association studies (GWAS) to search for genetic variation affecting the susceptibility to m...
Autores principales: | Adkins, Daniel E., Åberg, Karolina, McClay, Joseph L., Bukszár, József, Zhao, Zhongming, Jia, Peilin, Stroup, T. Scott, Perkins, Diana, McEvoy, Joseph P., Lieberman, Jeffrey A., Sullivan, Patrick F., van den Oord, Edwin J.C.G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891163/ https://www.ncbi.nlm.nih.gov/pubmed/20195266 http://dx.doi.org/10.1038/mp.2010.14 |
Ejemplares similares
-
Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics
por: McClay, Joseph L., et al.
Publicado: (2009) -
Genome-wide association study of antipsychotic induced QTc interval prolongation
por: Åberg, Karolina, et al.
Publicado: (2010) -
Estimation of CpG coverage in whole methylome next-generation sequencing studies
por: van den Oord, Edwin JCG, et al.
Publicado: (2013) -
Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR(*)D
por: Adkins, D E, et al.
Publicado: (2012) -
Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)